A Phase 1/2 interventional study of Abemaciclib and Irinotecan in Relapsed Solid Tumor and Refractory Solid Tumor, sponsored by Eli Lilly and Company. Completed at 25 sites in 8 countries. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing temozolomide in Sarcoma, Ewing — 3 open to participants now, 5 under way, none of them phase 3. Temozolomide · Sarcoma, Ewing.
Among the 14 studies testing temozolomide in Sarcoma, Ewing, this one is the 6th largest by enrollment, is the only one that started in 2020, is one of 3 in phase 1/2, and was the 10th registered.
250 studies on the registry are indexed under Sarcoma, Ewing; 69 are open to participants now.
Browse Sarcoma, Ewing studies →3 of the 14 studies testing temozolomide in Sarcoma, Ewing are open now, in 3 countries. Recruiting first, the newest first:
H. Lee Moffitt Cancer Center and Research Institute · Sites in United States
Ages 1+
Sun Yat-sen University · Sites in China
Ages 18–75
St. Jude Children's Research Hospital · Sites in United States, Canada
Ages 12 mo–30 yrs
By country, each count listing its studies:
Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 58 Sarcoma, Ewing studies recruiting now, 19 (33%) set no upper age limit and 36 (62%) stop at 75 or younger; 49 take children under 18; 2 take healthy volunteers.
This study: Up to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 1
First in 2006; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is above the median of 36 across 204 interventional studies indexed under Sarcoma, Ewing.
Median enrollment 39 across the 14 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 4 studies filed under Sarcoma, Ewing — fewer than ten, so there is no comparison to draw.
3 of the studies testing temozolomide in Sarcoma, Ewing that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04901702St. Jude Children's Research HospitalStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | 2026-12-31 |
| NCT06827717Sun Yat-sen UniversityPhase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma | 2027-04 |
| NCT01864109Memorial Sloan Kettering Cancer CenterIrinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing temozolomide in Sarcoma, Ewing, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment. For each participant, the study is estimated to last up to 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Parts A and B only:
Part C only:
All Parts
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received: * Abemaciclib: 70 mg/m², administered orally twice daily (BID). * Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.
Drug: Abemaciclib · Drug: Irinotecan · Drug: Temozolomide
Participants received: * Abemaciclib: 55 mg/m², administered orally BID. * Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.
Drug: Abemaciclib · Drug: Irinotecan · Drug: Temozolomide
Participants received: * Abemaciclib: 70 mg/m², administered orally BID. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.
Drug: Abemaciclib · Drug: Temozolomide
Participants received: * Abemaciclib: 90 mg/m², administered orally BID. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.
Drug: Abemaciclib · Drug: Temozolomide
Participants received: * Abemaciclib: 115 mg/m², administered orally BID. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.
Drug: Abemaciclib · Drug: Temozolomide
Participants received: * Abemaciclib: 115 mg/m², administered orally BID. * Temozolomide: 150 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.
Drug: Abemaciclib · Drug: Temozolomide
Participants received: * Abemaciclib: 55 mg/m², administered orally BID. * Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. * Dinutuximab: 17.5mg/m²/day, administered IV on Days 2-5 of each cycle. * Granulocyte-macrophage colony-stimulating factor (GM-CSF): 250 μg/m²/day, administered subcutaneously (SC) on Days 6-12 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.
Drug: Abemaciclib · Drug: Irinotecan · Drug: Temozolomide · Drug: Dinutuximab · Drug: GM-CSF
Administered orally
Also known as: LY2835219
Administered IV
Administered orally
Administered IV
Administered SC
Recommended Phase 2 Dose (RP2D) of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A)
The RP2D of abemaciclib was determined based on the totality of safety, tolerability, and pharmacokinetic results. RP2D of abemaciclib in combination with 50 mg/m²/day irinotecan and 100 mg/m²/day temozolomide on days 1-5 of 21-day cycles was reported.
Time frame: Cycles 1 and 2 (21 Day Cycles)
Number or Participants With Dose Limiting Toxicities (DLTs) in Part A
DLT was 1 of the following adverse events likely related to abemaciclib/combination and fulfils any 1 of the following criteria graded per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0: * Any non-hematologic Grade (G) ≥3 toxicity, except: * G3 diarrhea lasting \<72 hour (h) * Acute irinotecan-associated diarrhea lasting \<7 days * G≥3 nausea, vomiting, constipation that lasts \<72 h * G3 mucositis/stomatitis lasting \<72 h * G3 fever/infection * G≥3 electrolyte abnormality that lasts \<72 h, is not complicated, and resolves spontaneously or responds to conventional medication; * G≥3 amylase/lipase that is not associated with symptoms/clinical manifestations of pancreatitis; or * AST/ALT elevation resolving to eligibility criteria within 7 days; * Hematologic toxicities considered a DLT: * A \>14-day Cycle 2 delay due to neutropenia/thrombocytopenia * G≥3 thrombocytopenia with significant bleeding; or * G≥ 4 neutropenic fever
Time frame: Cycle 1 (21 Day Cycle)
Maximum Tolerated Dose (MTD) of Abemaciclib in Part A
The MTD was defined as the highest dose level at which less than 33% of participants experienced a DLT.
Time frame: Cycle 1 (21 Days)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Tlast (AUC0-tlast) of Abemaciclib in Part A
PK: (AUC0-tlast) was reported.
Time frame: Pre-dose, 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
PK: (AUC0-tlast) of Irinotecan in Part A
PK: AUC0-tlast) was reported.
Time frame: 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
PK: (AUC0-tlast) of Temozolomide in Part A
PK: AUC0-tlast was reported.
Time frame: 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
RP2D of Abemaciclib in Combination With Temozolomide (Part B)
The RP2D of abemaciclib was determined based on the totality of safety, tolerability, and pharmacokinetic results. RP2D of abemaciclib in combination with 150 mg/m²/day temozolomide on days 1-5 of 21-day cycles was reported.
Time frame: Cycles 1 and 2 (21 Day Cycles)
Number or Participants With DLTs in Part B
A DLT was 1 of the following adverse events likely related to abemaciclib/combination and fulfils any 1 of the following criteria graded as per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0: * Any non-hematologic Grade (G) ≥3 toxicity, except: * G3 diarrhea lasting \<72 hr * Acute irinotecan-associated diarrhea lasting \<7 days * G≥3 nausea, vomiting, constipation that lasts \<72 hr * G3 mucositis/stomatitis lasting \<72 hr * G3 fever/infection * G≥3 electrolyte abnormality that lasts \<72 hr, is not complicated, and resolves spontaneously or responds to conventional medication; * G≥3 amylase/lipase that is not associated with symptoms/clinical manifestations of pancreatitis; or * AST/ALT elevation resolving to eligibility criteria within 7 days; * Hematologic toxicities considered a DLT: * A \>14-day Cycle 2 delay due to neutropenia/thrombocytopenia * G≥3 thrombocytopenia with significant bleeding; or * G≥ 4 neutropenic fever
Time frame: Cycle 1 (21 Day Cycle)
MTD of Abemaciclib in Part B
The MTD was defined as the highest dose level at which less than 33% of participants experienced a DLT.
Time frame: Cycle 1 (21 Days)
PK: AUC0-tlast of Abemaciclib in Part B
PK: AUC0-tlast was reported.
Time frame: Pre-dose, 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
PK: AUC0-tlast of Temozolomide in Part B
PK: AUC0-tlast was reported.
Time frame: 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
Number of Participants With Overall Response Rate (ORR) in Part C.
ORR: Number of participants with best response of Complete Response (CR), Partial Response (PR), or Minor Response (MR) per International Neuroblastoma Response Criteria (INRC). * CR is defined as complete response in all response components: * Primary Tumor: \<10 mm residual soft tissue primary site and complete resolution of MIBG-avid tumors * Soft tissue and bone metastatic response: nonprimary target and nontarget lesions \<10 mm and nodes identified as targets decreased to short axis \<10mm and MIBG-avid update of nonprimary lesions completely resolved * Bone marrow response: no tumor infiltration on reassessment; disappearance of all target lesions; * PR is defined as PR in \>1component and all other components are either CR, minimal disease (MD) (bone marrow only), PR (soft tissue or bone), or not involved (NI) and no components with progressive disease (PD). * MR is defined PR or CR in \>1 component and SD in \>1 component and no component with PD
Time frame: Date of first dose to disease progression or death (Up to 25 Months)
Percentage of Participants With Overall Response Rate (ORR): Part A
ORR: Percentage of participants with best response of CR or PR per Response Evaluation Criteria in Solid Tumors (RECIST) or Response Assessment in Neuro-Oncology (RANO). RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).
Time frame: Date of first dose to disease progression or death (Up to 25 Months)
Percentage of Participants With ORR: Part B
ORR: Percentage of participants with best response of CR or PR per Response Evaluation Criteria in Solid Tumors (RECIST) or Response Assessment in Neuro-Oncology (RANO). RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).
Time frame: Date of first dose to disease progression or death (Up to 25 Months)
Duration of Response (DoR): Parts A and B.
DoR is the time between first evidence of CR or PR and disease progression or death due to any cause. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).
Time frame: Date of first evidence of a CR or PR to date of objective disease progression or death due to any cause (Up to 25 Months)
Duration of Response (DoR): Part C
DoR is the time between first evidence of CR, PR or MR and disease progression or death due to any cause. CR, PR, and MR was as per International Neuroblastoma Response Criteria (INRC). \- CR is defined as complete response in all response components: Primary Tumor: \<10 mm residual soft tissue primary site and complete resolution of MIBG-avid tumors Soft tissue and bone metastatic response: nonprimary target and nontarget lesions \<10 mm and nodes identified as targets decreased to short axis \<10mm and MIBG-avid update of nonprimary lesions completely resolved Bone marrow response: no tumor infiltration on reassessment; disappearance of all target lesions; * PR is defined as PR in \>1 component and all other components are either CR, minimal disease (MD) (bone marrow only), PR (soft tissue or bone), or not involved (NI) and no components with progressive disease (PD). * MR is defined PR or CR in \>1 component and SD in \>1 component and no component with PD
Time frame: Date of first evidence of a CR, PR, or MR to date of objective disease progression or death due to any cause (Up to 25 Months)
Percentage of Participants With Clinical Benefit Rate (CBR): Part A
The CBR is the percentage of participants with a best response of CR or PR, or Stable Disease (SD) for at least 6 months. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.
Time frame: Date of first dose to disease progression or death due to any cause (Up to 25 Months)
Percentage of Participants With CBR: Part B
The CBR is the percentage of participants with a best response of CR or PR, or SD for at least 6 months. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.
Time frame: Date of first dose to disease progression or death due to any cause (Up to 25 Months)
Percentage of Participants With Disease Control Rate (DCR): Part A
DCR: Percentage of participants with a best overall response of CR, PR, and SD. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.
Time frame: Date of first dose to measured progressive disease (Up to 25 Months)
Percentage of Participants With DCR: Part B
DCR: Percentage of participants with a best overall response of CR, PR, and SD. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.
Time frame: Date of first dose to measured progressive disease (Up to 25 Months)
Progression-Free Survival (PFS): Part C
Progression-free survival is measured as the time from first dose of study drug to progressive disease or death, whichever occurs first. PFS for Part C was reported.
Time frame: Date of first dose to progressive disease or death (Up to 25 Months)
Abemaciclib Tablet Acceptability
Participants were evaluated for abemaciclib acceptability (palatability and ease of administration) by asking a question - " Was it easy or difficult for the study subject to swallow the abemaciclib today?" Participants or their caregivers or both could respond using the following possible answers: Very difficult, difficult, neither easy nor difficult, easy, or very easy.
Time frame: Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (21 Day Cycles)
| Milestone | Part A Cohort A1 | Part A Cohort A-1 | Part B Cohort B1 | Part B Cohort B2 | Part B Cohort B3 | Part B Cohort B5 | Part C Cohort C1 |
|---|---|---|---|---|---|---|---|
| Started | 7 | 13 | 3 | 9 | 3 | 11 | 1 |
| Received at least one dose of study drug | 7 | 13 | 3 | 9 | 3 | 11 | 1 |
| Completed | 7 | 12 | 3 | 7 | 3 | 10 | 0 |
| Not completed | 0 | 1 | 0 | 2 | 0 | 1 | 1 |
| Withdrew: Discontinued study treatment, but follow-up visit was not completed due to primary study condition | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by parent/subject | 0 | 1 | 0 | 2 | 0 | 0 | 1 |
The RP2D of abemaciclib was determined based on the totality of safety, tolerability, and pharmacokinetic results. RP2D of abemaciclib in combination with 50 mg/m²/day irinotecan and 100 mg/m²/day temozolomide on days 1-5 of 21-day cycles was reported.
| milligrams/squared meters (mg/m²) BID | Part A - Abemaciclib |
|---|---|
| Recommended Phase 2 Dose (RP2D) of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) | 55 |
DLT was 1 of the following adverse events likely related to abemaciclib/combination and fulfils any 1 of the following criteria graded per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0: * Any non-hematologic Grade (G) ≥3 toxicity, except: * G3 diarrhea lasting \<72 hour (h) * Acute irinotecan-associated diarrhea lasting \<7 days * G≥3 nausea, vomiting, constipation that lasts \<72 h * G3 mucositis/stomatitis lasting \<72 h * G3 fever/infection * G≥3 electrolyte abnormality that lasts \<72 h, is not complicated, and resolves spontaneously or responds to conventional medication; * G≥3 amylase/lipase that is not associated with symptoms/clinical manifestations of pancreatitis; or * AST/ALT elevation resolving to eligibility criteria within 7 days; * Hematologic toxicities considered a DLT: * A \>14-day Cycle 2 delay due to neutropenia/thrombocytopenia * G≥3 thrombocytopenia with significant bleeding; or * G≥ 4 neutropenic fever
| Participants | Part A Cohort A1 | Part A Cohort A-1 |
|---|---|---|
| Number or Participants With Dose Limiting Toxicities (DLTs) in Part A | 3 | 1 |
The MTD was defined as the highest dose level at which less than 33% of participants experienced a DLT.
| mg/m² BID | Part A - Abemaciclib |
|---|---|
| Maximum Tolerated Dose (MTD) of Abemaciclib in Part A | 55 |
PK: (AUC0-tlast) was reported.
| nanogram *hour per milliliter (ng*h/mL) | Part A: 70 mg/m² Abemaciclib | Part A: 55 mg/m² Abemaciclib |
|---|---|---|
| Cycle 1, Day 1 | 730 ± 33 | 534 ± 116 |
| Cycle 2, Day 1 | NA ± NA | 757 ± 100 |
PK: AUC0-tlast) was reported.
| ng*h/mL | Part A: 50 mg/m²/Day Irinotecan |
|---|---|
| Cycle 1, Day 1 | 1450 ± 37 |
| Cycle 2, Day 1 | 1240 ± 58 |
PK: AUC0-tlast was reported.
| ng*h/mL | Part A: 100 mg/m²/Day Temozolomide |
|---|---|
| Cycle 1, Day 1 | 14400 ± 23 |
| Cycle 2, Day 1 | 12200 ± 44 |
The RP2D of abemaciclib was determined based on the totality of safety, tolerability, and pharmacokinetic results. RP2D of abemaciclib in combination with 150 mg/m²/day temozolomide on days 1-5 of 21-day cycles was reported.
| mg/m² BID | Part B - Abemaciclib |
|---|---|
| RP2D of Abemaciclib in Combination With Temozolomide (Part B) | 115 |
A DLT was 1 of the following adverse events likely related to abemaciclib/combination and fulfils any 1 of the following criteria graded as per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0: * Any non-hematologic Grade (G) ≥3 toxicity, except: * G3 diarrhea lasting \<72 hr * Acute irinotecan-associated diarrhea lasting \<7 days * G≥3 nausea, vomiting, constipation that lasts \<72 hr * G3 mucositis/stomatitis lasting \<72 hr * G3 fever/infection * G≥3 electrolyte abnormality that lasts \<72 hr, is not complicated, and resolves spontaneously or responds to conventional medication; * G≥3 amylase/lipase that is not associated with symptoms/clinical manifestations of pancreatitis; or * AST/ALT elevation resolving to eligibility criteria within 7 days; * Hematologic toxicities considered a DLT: * A \>14-day Cycle 2 delay due to neutropenia/thrombocytopenia * G≥3 thrombocytopenia with significant bleeding; or * G≥ 4 neutropenic fever
| Participants | Part B Cohort B1 | Part B Cohort B2 | Part B Cohort B3 | Part B Cohort B5 |
|---|---|---|---|---|
| Number or Participants With DLTs in Part B | 0 | 1 | 0 | 1 |
The MTD was defined as the highest dose level at which less than 33% of participants experienced a DLT.
| mg/m² BID | Part B - Abemaciclib |
|---|---|
| MTD of Abemaciclib in Part B | NA |
PK: AUC0-tlast was reported.
| ng*h/mL | Part B: 70 mg/m² Abemaciclib | Part B: 90 mg/m² Abemaciclib | Part B: 115 mg/m² Abemaciclib |
|---|---|---|---|
| Cycle 1, Day 1 | 566 ± 104 | 728 ± 60 | 728 ± 77 |
| Cycle 2, Day 1 | NA ± NA | 600 ± 27 | 1060 ± 57 |
PK: AUC0-tlast was reported.
| ng*h/mL | Part B: 100 mg/m²/Day Temozolomide | Part B: 150 mg/m²/Day Temozolomide |
|---|---|---|
| Cycle 1, Day 1 | 15800 ± 19 | 24300 ± 13 |
| Cycle 2, Day 1 | 15700 ± 21 | 21100 ± 43 |
ORR: Number of participants with best response of Complete Response (CR), Partial Response (PR), or Minor Response (MR) per International Neuroblastoma Response Criteria (INRC). * CR is defined as complete response in all response components: * Primary Tumor: \<10 mm residual soft tissue primary site and complete resolution of MIBG-avid tumors * Soft tissue and bone metastatic response: nonprimary target and nontarget lesions \<10 mm and nodes identified as targets decreased to short axis \<10mm and MIBG-avid update of nonprimary lesions completely resolved * Bone marrow response: no tumor infiltration on reassessment; disappearance of all target lesions; * PR is defined as PR in \>1component and all other components are either CR, minimal disease (MD) (bone marrow only), PR (soft tissue or bone), or not involved (NI) and no components with progressive disease (PD). * MR is defined PR or CR in \>1 component and SD in \>1 component and no component with PD
| Participants | Part C Cohort C1 |
|---|---|
| Number of Participants With Overall Response Rate (ORR) in Part C. | 1 |
ORR: Percentage of participants with best response of CR or PR per Response Evaluation Criteria in Solid Tumors (RECIST) or Response Assessment in Neuro-Oncology (RANO). RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).
| Percentage of participants | Part A Cohort A1 | Part A Cohort A-1 |
|---|---|---|
| Percentage of Participants With Overall Response Rate (ORR): Part A | 0 (NA to NA) | 7.7 (0.0 to 22.2) |
ORR: Percentage of participants with best response of CR or PR per Response Evaluation Criteria in Solid Tumors (RECIST) or Response Assessment in Neuro-Oncology (RANO). RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).
| Percentage of participants | Part B Cohort B1 | Part B Cohort B2 | Part B Cohort B3 | Part B Cohort B5 |
|---|---|---|---|---|
| Percentage of Participants With ORR: Part B | 0 (NA to NA) | 0 (NA to NA) | 33.3 (0.0 to 86.7) | 18.2 (0.0 to 41.0) |
DoR is the time between first evidence of CR or PR and disease progression or death due to any cause. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).
| Months | Part A Cohort A1 | Part A Cohort A-1 | Part B Cohort B1 | Part B Cohort B2 | Part B Cohort B3 | Part B Cohort B5 |
|---|---|---|---|---|---|---|
| Duration of Response (DoR): Parts A and B. | — | 22.59 (NA to NA) | — | — | 7.82 (NA to NA) | 0.03 (NA to NA) |
DoR is the time between first evidence of CR, PR or MR and disease progression or death due to any cause. CR, PR, and MR was as per International Neuroblastoma Response Criteria (INRC). \- CR is defined as complete response in all response components: Primary Tumor: \<10 mm residual soft tissue primary site and complete resolution of MIBG-avid tumors Soft tissue and bone metastatic response: nonprimary target and nontarget lesions \<10 mm and nodes identified as targets decreased to short axis \<10mm and MIBG-avid update of nonprimary lesions completely resolved Bone marrow response: no tumor infiltration on reassessment; disappearance of all target lesions; * PR is defined as PR in \>1 component and all other components are either CR, minimal disease (MD) (bone marrow only), PR (soft tissue or bone), or not involved (NI) and no components with progressive disease (PD). * MR is defined PR or CR in \>1 component and SD in \>1 component and no component with PD
| Months | Part C Cohort C1 |
|---|---|
| Duration of Response (DoR): Part C | 1.61 (NA to NA) |
The CBR is the percentage of participants with a best response of CR or PR, or Stable Disease (SD) for at least 6 months. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.
| Percentage of participants | Part A Cohort A1 | Part A Cohort A-1 |
|---|---|---|
| Percentage of Participants With Clinical Benefit Rate (CBR): Part A | 14.3 (0.0 to 40.2) | 30.8 (5.7 to 55.9) |
The CBR is the percentage of participants with a best response of CR or PR, or SD for at least 6 months. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.
| Percentage of participants | Part B Cohort B1 | Part B Cohort B2 | Part B Cohort B3 | Part B Cohort B5 |
|---|---|---|---|---|
| Percentage of Participants With CBR: Part B | 33.3 (0.0 to 86.7) | 0 (NA to NA) | 33.3 (0.0 to 86.7) | 18.2 (0.0 to 41.0) |
DCR: Percentage of participants with a best overall response of CR, PR, and SD. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.
| Percentage of participants | Part A Cohort A1 | Part A Cohort A-1 |
|---|---|---|
| Percentage of Participants With Disease Control Rate (DCR): Part A | 71.4 (38.0 to 100.0) | 53.8 (26.7 to 80.9) |
DCR: Percentage of participants with a best overall response of CR, PR, and SD. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.
| Percentage of participants | Part B Cohort B1 | Part B Cohort B2 | Part B Cohort B3 | Part B Cohort B5 |
|---|---|---|---|---|
| Percentage of Participants With DCR: Part B | 33.3 (0.0 to 86.7) | 55.6 (23.1 to 88.0) | 100 (100.0 to 100.0) | 36.4 (7.9 to 64.8) |
Progression-free survival is measured as the time from first dose of study drug to progressive disease or death, whichever occurs first. PFS for Part C was reported.
| Months | Part C Cohort C1 |
|---|---|
| Progression-Free Survival (PFS): Part C | 2.9 |
Participants were evaluated for abemaciclib acceptability (palatability and ease of administration) by asking a question - " Was it easy or difficult for the study subject to swallow the abemaciclib today?" Participants or their caregivers or both could respond using the following possible answers: Very difficult, difficult, neither easy nor difficult, easy, or very easy.
| Participants | Part A Cohort A1 (Caregiver Responses - Cycle 1 Day 1) | Part A Cohort A1 (Caregiver Responses - Cycle 1 Day 15) | Part A Cohort A1 (Caregiver Responses - Cycle 2 Day 1) | Part A Cohort A1 (Participant Responses - Cycle 1 Day 1) | Part A Cohort A1 (Participant Responses - Cycle 1 Day 15) | Part A Cohort A1 (Participant Responses - Cycle 2 Day 1) | Part A Cohort A-1(Caregiver Responses - Cycle 1 Day 1) | Part A Cohort A-1(Caregiver Responses - Cycle 1 Day 15) | Part A Cohort A-1(Caregiver Responses - Cycle 2 Day 1) | Part A Cohort A-1(Participant Responses - Cycle 1 Day 1) | Part A Cohort A-1(Participant Responses - Cycle 1 Day 15) | Part A Cohort A-1(Participant Responses - Cycle 2 Day 1) | Part B Cohort B1 (Caregiver Responses - Cycle 1 Day 1) | Part B Cohort B1 (Caregiver Responses - Cycle 1 Day 15) | Part B Cohort B1 (Caregiver Responses - Cycle 2 Day 1) | Part B Cohort B1 (Participant Responses - Cycle 1 Day 1) | Part B Cohort B1 (Participant Responses - Cycle 1 Day 15) | Part B Cohort B1 (Participant Responses - Cycle 2 Day 1) | Part B Cohort B2 (Caregiver Responses - Cycle 1 Day 1) | Part B Cohort B2 (Caregiver Responses - Cycle 1 Day 15) | Part B Cohort B2 (Caregiver Responses - Cycle 2 Day 1) | Part B Cohort B2 (Participant Responses - Cycle 1 Day 1) | Part B Cohort B2 (Participant Responses - Cycle 1 Day 15) | Part B Cohort B2 (Participant Responses - Cycle 2 Day 1) | Part B Cohort B3 (Caregiver Responses - Cycle 1 Day 1) | Part B Cohort B3 (Caregiver Responses - Cycle 1 Day 15) | Part B Cohort B3 (Caregiver Responses - Cycle 2 Day 1) | Part B Cohort B3 (Participant Responses - Cycle 1 Day 1) | Part B Cohort B3 (Participant Responses - Cycle 1 Day 15) | Part B Cohort B3 (Participant Responses - Cycle 2 Day 1) | Part B Cohort B5 (Caregiver Responses - Cycle 1 Day 1) | Part B Cohort B5 (Caregiver Responses - Cycle 1 Day 15) | Part B Cohort B5 (Caregiver Responses - Cycle 2 Day 1) | Part B Cohort B5 (Participant Responses - Cycle 1 Day 1) | Part B Cohort B5 (Participant Responses - Cycle 1 Day 15) | Part B Cohort B5 (Participant Responses - Cycle 2 Day 1) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Very easy to swallow tablet | 1 | 1 | 3 | 4 | 4 | 4 | 6 | 4 | 6 | 6 | 4 | 5 | 1 | 0 | 0 | 2 | 1 | 2 | 3 | 3 | 2 | 5 | 5 | 3 | 0 | 1 | 1 | 3 | 3 | 3 | 3 | 6 | 4 | 6 | 8 | 9 |
| Easy to swallow tablet | 2 | 1 | 2 | 3 | 1 | 2 | 0 | 0 | 1 | 4 | 3 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 |
| Neither easy nor difficult to swallow tablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 |
| Difficult to swallow tablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Very difficult to swallow tablet | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Collected over Baseline Up To 2.2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Cohort A1 | 1/7 (14.3%) | 3/7 (42.9%) | 7/7 (100%) |
| Part A Cohort A-1 | 1/13 (7.7%) | 5/13 (38.5%) | 13/13 (100%) |
| Part B Cohort B1 | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Part B Cohort B2 | 1/9 (11.1%) | 0/9 (0%) | 8/9 (88.9%) |
| Part B Cohort B3 | 1/3 (33.3%) | 0/3 (0%) | 3/3 (100%) |
| Part B Cohort B5 | 2/11 (18.2%) | 4/11 (36.4%) | 11/11 (100%) |
| Part C Cohort C1 | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Event | Part A Cohort A1 | Part A Cohort A-1 | Part B Cohort B1 | Part B Cohort B2 | Part B Cohort B3 | Part B Cohort B5 | Part C Cohort C1 |
|---|---|---|---|---|---|---|---|
| Vancomycin infusion reactionSkin and subcutaneous tissue disorders | 0/7 | 0/13 | 0/3 | 0/9 | 0/3 | 0/11 | 1/1 |
| VomitingGastrointestinal disorders | 0/7 | 1/13 | 1/3 | 0/9 | 0/3 | 1/11 | 0/1 |
| PyrexiaGeneral disorders | 0/7 | 1/13 | 1/3 | 0/9 | 0/3 | 0/11 | 0/1 |
| Depressed level of consciousnessNervous system disorders | 0/7 | 0/13 | 1/3 | 0/9 | 0/3 | 0/11 | 0/1 |
| SeizureNervous system disorders | 0/7 | 1/13 | 1/3 | 0/9 | 0/3 | 0/11 | 0/1 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/7 | 1/13 | 0/3 | 0/9 | 0/3 | 0/11 | 0/1 |
| DiarrhoeaGastrointestinal disorders | 1/7 | 0/13 | 0/3 | 0/9 | 0/3 | 0/11 | 0/1 |
| Abdominal painGastrointestinal disorders | 0/7 | 0/13 | 0/3 | 0/9 | 0/3 | 1/11 | 0/1 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/7 | 0/13 | 0/3 | 0/9 | 0/3 | 1/11 | 0/1 |
| Respiratory syncytial virus infectionInfections and infestations | 0/7 | 0/13 | 0/3 | 0/9 | 0/3 | 1/11 | 0/1 |
| Event | Part A Cohort A1 | Part A Cohort A-1 | Part B Cohort B1 | Part B Cohort B2 | Part B Cohort B3 | Part B Cohort B5 | Part C Cohort C1 |
|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 5/7 | 8/13 | 1/3 | 5/9 | 2/3 | 7/11 | 1/1 |
| NeutropeniaBlood and lymphatic system disorders | 6/7 | 10/13 | 2/3 | 6/9 | 3/3 | 8/11 | 1/1 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/7 | 8/13 | 2/3 | 4/9 | 2/3 | 9/11 | 1/1 |
| AnisocoriaEye disorders | 0/7 | 0/13 | 0/3 | 0/9 | 0/3 | 0/11 | 1/1 |
| Abdominal painGastrointestinal disorders | 4/7 | 6/13 | 1/3 | 2/9 | 2/3 | 4/11 | 1/1 |
| DiarrhoeaGastrointestinal disorders | 7/7 | 13/13 | 0/3 | 5/9 | 3/3 | 9/11 | 0/1 |
| NauseaGastrointestinal disorders | 5/7 | 5/13 | 0/3 | 2/9 | 1/3 | 4/11 | 1/1 |
| VomitingGastrointestinal disorders | 6/7 | 7/13 | 1/3 | 6/9 | 2/3 | 6/11 | 1/1 |
| FatigueGeneral disorders | 1/7 | 5/13 | 1/3 | 2/9 | 0/3 | 2/11 | 1/1 |
| PainGeneral disorders | 1/7 | 0/13 | 0/3 | 0/9 | 0/3 | 0/11 | 1/1 |
All participants who received at least one dose of the study drug.
| Age, Continuous(years) | Part A Cohort A1 | Part A Cohort A-1 | Part B Cohort B1 | Part B Cohort B2 | Part B Cohort B3 | Part B Cohort B5 | Part C Cohort C1 | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 12.9 ± 3.3 | 12.2 ± 3.2 | 12.3 ± 4.7 | 12.2 ± 4.4 | 9.3 ± 3.5 | 9.8 ± 4.5 | 7.00 | 11.4 ± 3.9 |
| Sex: Female, Male(Participants) | Part A Cohort A1 | Part A Cohort A-1 | Part B Cohort B1 | Part B Cohort B2 | Part B Cohort B3 | Part B Cohort B5 | Part C Cohort C1 | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 2 | 6 | 2 | 4 | 3 | 6 | 0 | 23 |
| Male | 5 | 7 | 1 | 5 | 0 | 5 | 1 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Part A Cohort A1 | Part A Cohort A-1 | Part B Cohort B1 | Part B Cohort B2 | Part B Cohort B3 | Part B Cohort B5 | Part C Cohort C1 | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 0 | 1 | 2 | 2 | 0 | 7 |
| Not Hispanic or Latino | 7 | 7 | 2 | 8 | 1 | 9 | 1 | 35 |
| Unknown or Not Reported | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 5 |
| Race (NIH/OMB)(Participants) | Part A Cohort A1 | Part A Cohort A-1 | Part B Cohort B1 | Part B Cohort B2 | Part B Cohort B3 | Part B Cohort B5 | Part C Cohort C1 | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 3 | 0 | 1 | 0 | 0 | 0 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 4 | 7 | 2 | 8 | 3 | 11 | 1 | 36 |
| More than one race | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 3 |
| Region of Enrollment(Participants) | Part A Cohort A1 | Part A Cohort A-1 | Part B Cohort B1 | Part B Cohort B2 | Part B Cohort B3 | Part B Cohort B5 | Part C Cohort C1 | Total |
|---|---|---|---|---|---|---|---|---|
| France | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| Germany | 2 | 1 | 0 | 4 | 0 | 1 | 0 | 8 |
| Italy | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 3 |
| Japan | 3 | 1 | 0 | 1 | 0 | 0 | 0 | 5 |
| Spain | 2 | 7 | 2 | 3 | 3 | 10 | 0 | 27 |
| United States | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2020 to primary completion in Mar 2024, 40 months.
Results were first posted in Aug 2025, 1 year 4 months after primary completion.
Of 27 phase 1/2 interventional studies under Sarcoma, Ewing, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 84. This study's 40 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abemaciclib · Temozolomide